May 12, 2026 The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
May 9, 2026 Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
May 2, 2026 Nine-Protein Plasma Signature Predicts Kidney Events and Mortality in High-Risk APOL1 Patients
